Know Cancer

or
forgot password

Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples


N/A
N/A
N/A
Open (Enrolling)
Both
Malignant Melanoma

Thank you

Trial Information

Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples


Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the
largest comprehensive cancer centre in Europe. In addition to an in-house drug development
program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In
order to investigate the optimal use of novel molecularly targeted agents, access to
clinical tumour samples is needed in order to determine which particular cancer type
expresses a molecular "signature" that may indicate potential therapeutic utility.
Understanding such signatures should accelerate the registration of new drugs for routine
cancer therapy; offering the potential of selecting those patients with tumour types most
likely to benefit from therapy. Furthermore, new insights into disease biology may be
gained.

Main research question/ objective - Are there features of primary melanoma or lymph node
metastases that predict subsequent clinical outcome better than existing markers?


Inclusion Criteria:



- Diagnosis of melanoma

- Adequate paraffin-embedded material available for analysis.

- Adequate clinical follow-up information

- Written informed consent where applicable

Exclusion Criteria:

- Inadequate paraffin-embedded material available

- Inadequate clinical follow-up information.

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Retrospective

Outcome Measure:

Given that the nature of the research is qualitative, there is no primary outcome measure.

Safety Issue:

No

Principal Investigator

Professor Martin Gore

Investigator Role:

Principal Investigator

Investigator Affiliation:

Royal Marsden NHS Foundation Trust

Authority:

United Kingdom: Research Ethics Committee

Study ID:

CCR3078

NCT ID:

NCT01002560

Start Date:

December 2008

Completion Date:

December 2009

Related Keywords:

  • Malignant Melanoma
  • Melanoma
  • Novel Prognostic Markers
  • Melanoma

Name

Location